Imagion Receives Positive Feedback from FDA for HER2 Breast Cancer Phase 2 Clinical Trial
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® HER2
